LNC
IBB icon

Lincoln National Corp’s iShares Biotechnology ETF IBB Stock Holding History

Lincoln National Corp’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,016
Closed -$1.24M – 512
2024
Q1 		$1.24M Buy
9,016
+783
+10% +$107K 0.02% 452
2023
Q4 		$1.12M Sell
8,233
-1,398
-15% -$171K 0.02% 434
2023
Q3 		$1.18M Buy
9,631
+394
+4% +$50.1K 0.02% 368
2023
Q2 		$1.17M Buy
9,237
+129
+1% +$16.8K 0.02% 368
2023
Q1 		$1.18M Buy
9,108
+21
+0.2% +$2.75K 0.02% 345
2022
Q4 		$1.19M Buy
9,087
+2,780
+44% +$359K 0.03% 318
2022
Q3 		$737K Sell
6,307
-108
-2% -$13.4K 0.02% 393
2022
Q2 		$754K Sell
6,415
-1,832
-22% -$217K 0.02% 394
2022
Q1 		$1.07M Buy
8,247
+1,075
+15% +$140K 0.02% 343
2021
Q4 		$1.09M Buy
7,172
+326
+5% +$50.5K 0.02% 330
2021
Q3 		$1.11M Sell
6,846
-284
-4% -$47.8K 0.02% 308
2021
Q2 		$1.17M Buy
7,130
+244
+4% +$37.6K 0.03% 281
2021
Q1 		$1.04M Buy
6,886
+158
+2% +$25.1K 0.03% 286
2020
Q4 		$1.02M Sell
6,728
-52
-0.8% -$7.43K 0.03% 277
2020
Q3 		$918K Sell
6,780
-1,392
-17% -$189K 0.03% 267
2020
Q2 		$1.12M Buy
8,172
+1,394
+21% +$178K 0.04% 224
2020
Q1 		$730K Sell
6,778
-211
-3% -$24.3K 0.03% 266
2019
Q4 		$842K Buy
6,989
+1,611
+30% +$180K 0.03% 293
2019
Q3 		$535K Buy
5,378
+441
+9% +$46.2K 0.02% 330
2019
Q2 		$538K Buy
4,937
+2,183
+79% +$232K 0.02% 308
2019
Q1 		$308K Buy
2,754
+270
+11% +$29.6K 0.01% 384
2018
Q4 		$239K Buy
2,484
+706
+40% +$74.9K 0.01% 396
2018
Q3 		$217K Buy
+1,778
New +$209K 0.01% 439
2018
Q1 		– Sell
-4,755
Closed -$508K – 549
2017
Q4 		$508K Buy
4,755
+2,535
+114% +$271K 0.02% 366
2017
Q3 		$246K Buy
2,220
+150
+7% +$16K 0.01% 355
2017
Q2 		$214K Buy
+2,070
New +$204K 0.01% 322

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Lincoln National Corp's IBB Position: Q2 2024 in Review

Lincoln National Corp sold out of iShares Biotechnology ETF (IBB) in Q2 2024, closing a stake of 9,016 shares — an estimated $1.24M sold.

Lincoln National Corp first reported a position in IBB in Q2 2017 and held it in 26 quarters. The position peaked at $1.24M in Q1 2024. 894 funds tracked by Wall St. Rank hold IBB as of Q2 2024.

  • Lincoln National Corp reported no remaining iShares Biotechnology ETF position as of Q2 2024 after selling out during the quarter.
  • Lincoln National Corp sold 9,016 iShares Biotechnology ETF shares in Q2 2024, an estimated $1.24M.
  • Lincoln National Corp first reported a position in iShares Biotechnology ETF in Q2 2017 and held it in 26 quarters.
  • Lincoln National Corp's iShares Biotechnology ETF position peaked at $1.24M in Q1 2024.
  • 894 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2024.

Based on Lincoln National Corp's 13F filing for Q2 2024, filed 25 Jul 2024.